11 June 2018 - Department of Health and Human Services officials have been meeting with pharmaceutical companies to seek voluntary cuts in drug prices, according to sources familiar with the meetings.

Voluntary cuts in prices would allow the administration to immediately tout benefits of President Trump's drug pricing plan, which was announced last month, rather than having to wait for any regulatory actions to be put forward and take effect.

It is not yet clear whether any drug companies have agreed to cut their prices voluntarily.

Read The Hill article